glp-1 stock FDA Approves First Generic Liraglutide for Weight Loss GLP-1 Receptor Agonists Linked to
Description
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: phase 2 trial
Embrace a natural path to weight loss and well-being today
As of May 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with a public comment period closing June 29, 2026
Peer review Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work
Semaglutide, on the other hand, is one medicine in this group that people recognize for its high effectiveness and ability to work for a long time
References 1.Rowlands J., et al
